Mini-review

Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues – A mini-review

Mohamed El Kassas a,⇑, Tamer Elbaz b, Mohamed Salaheldin c, Lobna Abdelsalam d, Ahmed Kaseb e, Gamal Esmat b

a Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt
b Endemic Medicine and Hepatogastroenterology Department, Faculty of Medicine, Cairo University, Cairo, Egypt
c Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
d Genome Unit, Faculty of Medicine, Cairo University, Cairo, Egypt
e Department of Gastrointestinal Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Texas, USA

HIGHLIGHTS

- Conflicting reports are available for the likelihood of HCC recurrence after DAAs.
- Weak evidence is existing for the de novo occurrence of HCC following DAAs.
- Geographical and ethnic differences could explain variable results among studies.
- Observed marked heterogeneity in the design and inclusion criteria of studies.
- Identifying patients at increased risk is very important for the management of HCC.

ABSTRACT

Hepatitis C virus clearance is expected in more than 95% of patients treated with direct-acting antivirals (DAAs). However, an extensive debate about the impact of DAAs on the development of hepatocellular carcinoma (HCC) is currently ongoing. This review aimed to explore currently available evidence about the relationship between DAAs and HCC development. The American studies and some European studies clearly showed no relation, while the Japanese and Egyptian studies and the other European studies showed an increased risk of developing HCC after DAA exposure. These conflicting results may be due to geographical and ethnic variations and differences in the design and inclusion criteria among the studies. After reviewing the data from these different studies, it seems that some patients are at increased risk of developing HCC after DAA exposure. Identifying those at increased risk is very important for the management of HCC in light of the potentially major consequences of HCC for the patients’ quality of life and the subsequent major burden imposed on healthcare resources.

© 2019 The Authors. Published by Elsevier B.V. on behalf of Cairo University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Liver cirrhosis is the most common risk factor for hepatocellular carcinoma (HCC). Moreover, hepatitis C virus (HCV) is the leading cause of chronic liver disease in the United States, Europe, and many other countries like Egypt [1,2]. Hepatocarcinogenesis risk in HCV infected patients with advanced cirrhosis ranges from 2% to 8% per year [3]. One of the lessons learned during the era of interferon (IFN)-based therapy for hepatitis C virus (HVC) was that eradication of HCV reduced the risk of developing hepatocellular carcinoma (HCC), irrespective of the degree of hepatic fibrosis. This finding was demonstrated by multiple studies and meta-analyses [4,5]. Moreover, patients with previously ablated HCC who achieved a sustained virologic response (SVR) due to IFN-based therapy had better prognoses than those who did not [6]. Additionally, achieving a SVR has been found to be the single most important factor predicting a lower risk of developing HCV-induced HCC [7]. Notably, IFN-based therapy was limited to patients without advanced cirrhosis. The introduction of highly effective direct-acting antivirals (DAAs) was generally expected by practicing hepatologists to lead to the extension of this benefit to all patients, including those who were not candidates for IFN-based therapy [8]. However, the clinical experience of using DAAs has resulted in a major debate regarding the relationship between DAAs and the development of HCC. Many authors have suggested that there is a link between the use of DAAs and the development of HCC, while others have insisted that DAAs are protective against HCC development. In this review, we explored the available evidence to identify possible explanations for these conflicting viewpoints and to develop suggestions for future research needed to solve this ongoing debate.

Studies that suggested a link between HCC development/ recurrence and DAA therapy

HCC occurrence is defined as new appearance of HCC in patients with no history of liver tumor. While HCC recurrence is defined as reappearance of HCC in patients who had previous successful radical treatment for HCC [9]. In 2016, Reig and his colleagues published an initial report that showed an unexpectedly high recurrence rate of previously treated HCC. The authors retrospectively analysed a cohort of 58 patients who had previously received treatment for HCV-HCC followed by DAA-based HCV treatment. The study reported a 27.6% recurrence rate after a median follow-up of 5.7 months [10]. The major limitations of this study were using crude recurrence rate, including patients who received TACE therapy, which is a palliative treatment and finally using time of DAA initiation instead of time of HCC treatment as a baseline to calculate recurrence-free period [11]. This study was the first to reflect this risk of increased recurrence and it sparked global interest in conducting further research. This initial study was soon followed by another retrospective study from Italy by Conti et al. The study included 344 chronic HCV patients with cirrhosis who received different DAA regimens; 91% of the patients achieved a SVR. The patients were followed for 24 weeks. The authors reported a 29% recurrence rate for those with a history of HCC and a 3.16% incidence rate [de novo] in those without a history of prior HCC irrespective of DAA regimen used [12]. As this study had no control group, they compared their data with those of a historic cohort of untreated patients with cirrhosis at their centre. The historic cohort was found to have a 3.2% incidence rate of de novo HCC, which was similar to the rate among the chronic HCV patients without a history of prior HCC who received DAA therapy. The authors concluded that HCV eradication in patients with cirrhosis did not provide protection against the development of HCC. Similar results were reported by Cardoso et al. [13] and Kozibial et al. [14]; those studies reported 7.4% and 6.6% incidence rates of HCC within a-one and 2 years of follow-up, respectively, of patients with cirrhosis who received DAA. Moreover, Nakao and his colleagues reported 1.7% and 7% HCC incidence rates one and two years after DAA therapy, respectively, in 242 Japanese patients.

In another European study from Belgium, Bielen and his colleagues made an important observation. Although they found no difference in the HCC incidence rates between patients who received DAAs with or without pegylated (Peg)-IFN treatment, interestingly, they reported an HCC recurrence rate of 15% in patients treated with DAAs alone compared to 0% in those who received a combination of Peg-IFN (which is an immune-modulator) and DAAs [16]. Although selection bias could not be excluded in that study (patients who are not candidates for IFN-based therapy may have more advanced chronic liver disease and cirrhosis and therefore a higher HCC risk), it highlighted the potential role of immunomodulation in the recurrence of HCC after DAA therapy.

In 2017, reports from non-European countries emerged, and they supported the same hypothesis. Iida et al. [17] reported a 5% incidence rate and a 12% recurrence rate of HCC in a Japanese cohort with cirrhosis who were treated with daclatasvir and asunaprevir and followed for 15 months. Minami et al. [18] and Virlogeux et al. [19] reported the highest HCC recurrence rates (54.4% and 47.8%, respectively). The former followed 163 Japanese patients with a history of HCC for 14.5 months, and the latter included 23 French patients with cirrhosis; both studies included patients treated with TACE or radiotherapy. Kolly et al. [20] included patients from 3 European countries who were treated for HCC with ablation, resection or TACE. They reported a 42.5% recurrence rate after 21 months of follow-up. Similar observations were reported by Shimizu and his colleagues [21]. Additionally, Yang et al., in their small study with a total of 58 patients, noticed a 27.8% recurrence rate in patients who received bridge therapy before liver transplantation (LT) (ablation, TACE) [22], and Nagata et al. reported a 29% recurrence rate after a median follow-up of 27.6 months in patients who were treated with ablation or resection for early-stage HCC [23]. Finally, an Egyptian study reported that HCC recurrence was observed in 42% of 62 patients who were treated by DAAs after successful HCC management using one of the following modalities: 1. percutaneous ethanol injection (PEI), 2. thermal ablation by RFA or microwave ablation (MWA), 3. hepatic resection, and 4. TACE. More than 80% of these patients developed recurrence within 6 months of treatment initiation [24].

Notably, in addition to HCC recurrence, the biology of HCC and the pattern of recurrence after DAA treatment have been investigated. In 2017, Reig and colleagues reported that they found more aggressive HCC recurrence after DAA treatment, as defined by an advanced Barcelona Clinic Liver Cancer (BCLC) stage [25]. Additionally, Renzulli et al. found a more aggressive pattern of HCC recurrence with early vascular invasion after DAA therapy [26]. Abdelaziz and his colleagues noticed that compared with patients with de novo HCC after DAA therapy, patients with recurring HCC after DAA therapy had a lower 1-year survival rate and were less responsive to ablation therapy [27]. The annual incidence of HCC in patients with HCV-related cirrhosis is 2–8%, and after reviewing recent publications, we can conclude that no data showed an increase in the risk of HCC occurrence after DAA exposure.

Studies that found no link between HCC development/ recurrence and DAA therapy

Two large studies from the USA published in 2017 did not find any increase in the incidence of HCC after DAA therapy. Ioannou et al. retrospectively studied 62,354 HCV patients and found that...
achieving a SVR, regardless of the type of therapy (DAAs alone, DAAs in combination with IFN-based therapy or IFN-based therapy alone), reduced the risk of developing de novo HCC by 71% [28]. However, the study indicated that the risk of developing HCC was higher in patients with cirrhosis than in those without cirrhosis. Additionally, Kanwal et al. studied 22,500 patients and reported similar results [29]. None of these studies examined the rate of HCC recurrence. Another important large prospective study conducted by Calvaruso et al. in 2018 observed a 2.9% incidence rate of HCC after following 2249 patients with cirrhosis for one year [30]. They also confirmed the beneficial effects of HCV eradication in patients with different stages of cirrhosis and reported that patients with compensated cirrhosis without portal hypertension experienced a significant reduction in the HCC incidence rate after HCV eradication [30]. This was also confirmed by Romano and colleagues who followed 3917 HCV patients after DAA therapy with a mean follow-up period of 536 (±192) days. They reported that HCC occurrence rate was 0.46% in F3, 1.49% in CTP-A and 3.61% in CTP-B cirrhotics; in the first year [31]. Similarly, Hasson et al. did not observe any increase in the incidence of HCC in patients co-infected with HCV and HIV who were treated with DAAs [32]. Another large study conducted by Calleja and his colleagues, which included 4000 HCV patients who were treated with DAAs, confirmed a low incidence rate of de novo HCC (0.93%) but reported a 30% recurrence rate of HCC after 18 months of follow-up [33]. The study also indicated that HCC was more common in patients with cirrhosis, irrespective of their SVR status [33].

Furthermore, Nagata et al. studied 1897 Japanese patients and observed a 2.5% incidence rate of de novo HCC in patients who received IFN-free based therapy and a 1.1% incidence rate in those who received IFN-free therapy. Surprisingly, the same study found a 53% recurrence rate in the IFN-based group and a 29% recurrence rate in the IFN-free group [23]. Zavaglia et al. reported a 3.2% recurrence rate in their cohort of Italian patients who were treated with DAAs [34], while Torres et al. [35] found no HCC recurrence after a 12-month follow-up period. However, both studies lacked control groups and included small numbers of patients (32 patients in the former and 7 in the latter). Zeng et al. reported the same results in a letter to the editor of the Journal of Hepatology [36]. Notably, a prospective study by Ogawa et al. with 152 patients who received treatment for HCC (ablation, resection, TACE and radiotherapy) reported a 16.5% recurrence rate [37]. Another large prospective study conducted in Italy by Cabibbo and his colleagues with 143 patients and a 9-month median follow-up period found 12% and 53% recurrence rate in the IFN-based group and a 29% recurrence rate in the latter. They also confirmed the beneficial effects of HCV eradication after DAAs exposure in liver transplant recipients, an issue that is under investigation in published articles [40].

A systematic review and meta-analysis performed by Waziry et al. analysed 26 studies and found that there was no increased risk of developing HCC following DAA therapy in patients with cirrhosis. They reported a reduction in individual risk of 63% [41]. Although they found a higher HCC recurrence rate, they attributed this to a shorter duration of follow-up (cohort effect) and older age of the included patients (higher baseline risk). Notably, another important time-dependent analytical study from Egypt performed by our group in cooperation with the Emerging Disease Epidemiology Unit at the Institute Pasteur was recently published [8]. This was the first propensity score-matched comparative time-dependent analysis of DAA-exposed and non-exposed patients who were previously treated for HCC and confirmed to have achieved a complete radiological response. The major strengths of the study were as follows the exclusion of patients who were treated by non-curate options to manage HCC; the exclusion of those treated by IFN-based therapy combined with DAs; the initiation of follow-up from point of HCC eradication, according to the mRECIST criteria; the inclusion of a matched control group; and the adjustment for baseline factors and the time since complete radiological response of HCC through inverse probability weighting. Importantly, in contrast to the French data, our results showed a 4-fold increase in the rate of HCC recurrence after DAA treatment in patients with a history of successfully treated HCC when compared to the matched control patients who were not treated with DAs. Remarkably, after a median follow-up period of 16 months, a 37.7% recurrence rate was observed in DAA-exposed patients [8]. In this study there was no difference in recurrence rate in patients who received DAA early after HCC treatment (less than 3 months) and those who received it later (more than 6 months). However another report presented in international liver conference 2018 pointed to the importance of time elapsed since HCC complete response after treatment and HCC recurrence rate after DAA exposure but still waiting full data [42].

Potential pitfalls of studies and reasons of disparity in results

Collectively, most of the aforementioned studies, whether they supported or refuted the potential link between DAA therapy and HCC development/recurrence, share several common main limitations that can be summarized as follows:

- The studies lacked control groups;
- There was major heterogeneity within the groups of patients with HCC in terms of clinicopathologic features, such as cirrhosis grade, tumour morphology and HCC stage;
- Different HCC therapies were applied in the various studies, ranging from palliative TACE to potentially curative options such as ablation and surgery;
- Time elapsed between the presumed eradication of HCC and treatment with DAAs;
- The studies were retrospective rather than prospective; and
- There was variability in the analytical methods used [8].

Analytical studies

Analytical and comparative time-dependent studies may be more useful in solving this debate than retrospective studies; however, conflicting results of these studies remain a major challenge to drawing a firm conclusion. The first analytical study discussing this issue was conducted by Pol and colleagues, who compared DAA-exposed and non-exposed groups from the French ANRS Hepather cohort. They found no increased risk of recurrence in those exposed to DAAs (HR: 1.21, 95% CI 0.62-2.34). One major strength of this study was that they analysed 3 distinct cohorts, and their results were consistent among the three groups [40]. However, the study included patients who received DAAs at least 23 months after HCC treatment. Thus, they included patients with indolent HCC, and due to this delayed disease-free window, the tumours detected could be considered denovo HCC rather than recurrent disease. In their analysis they also reported that there was no increase in HCC recurrence after DAA exposure in liver transplant recipients, an issue that is under investigation in published articles [40].
Summary of studies that found predictors of HCC development after DAA exposure. See above-mentioned references for further information.

Table 1

| Study                  | Predictors for occurrence                                      | Predictors for recurrence                                      |
|------------------------|-----------------------------------------------------------------|----------------------------------------------------------------|
| Conti et al. [12]      | Liver cirrhosis, Child stage B,                                | Increased age, liver stiffness score                           |
|                        | Thrombocytopenia                                                | Previous HCC recurrence, baseline tumor size                   |
| Cabibbo et al. [38]    | N/A                                                             | Alpha-fetoprotein -L3, DCP, number of previous HCC management,  |
|                        |                                                                  | Time elapsed between last HCC treatment and DAA start          |
| Minami et al. [18]     | N/A                                                             |河道河内et (49)                                                |
| Kanwal et al. [29]     | Liver cirrhosis, alcohol use                                    |河道河内et (49)                                                |
| Ogawa et al. [37]      | N/A                                                             |河道河内et (49)                                                |
| Ikeda et al. [49]      | N/A                                                             |河道河内et (49)                                                |
| Mettke et al. [48]     | MELD score, Alpha-fetoprotein level                             |河道河内et (49)                                                |
| Kolly et al. [20]      | N/A                                                             |河道河内et (49)                                                |
| Nagata et al. [23]     | N/A                                                             |河道河内et (49)                                                |
| Calvaruso et al. [30]  | Hypoalbuminemia, absence of SVR,                                |河道河内et (49)                                                |
|                        | thrombocytopenia                                                |河道河内et (49)                                                |
| Shimizu et al. [21]    | N/A                                                             |河道河内et (49)                                                |
| Mashiba et al. [50]    | N/A                                                             |河道河内et (49)                                                |

What really happened according to available evidence?

Many explanations have been suggested; some authors linked the development of HCC to baseline risk factors such as advanced fibrosis grade, co-infection with hepatitis B virus (HBV) or age. Another hypothesis suggests that DAAs induce the dysregulation of immune surveillance mechanisms, following the very rapid viral clearance; this phenomenon has been confirmed by multiple studies. This dysregulation may result in the reconstitution of innate immunity, with the downregulation of type II and III IFNs, their receptors and IFN-stimulated genes. A reduction in the activation of IFN may, in turn, allow the growth of malignant cells due to the anti-angiogenic and anti-proliferative properties of IFN, which DAAs lack [43]. Additionally, one of the changes in the immune system that has been described after HCV eradication is the reduction in the numbers of cytotoxic activity of natural killer (NK) cells in the liver, which supports a faster progression of HCC foci [43]. This observation was emphasized by an interesting study performed by Monto and colleagues who noticed that all 11 patients who developed HCC after second generation DAA had NK cell inhibitory KIR/HLA types suggesting the genetic based impaired immune surveillance ability in those patients [44]. Another potential mechanism could be related to microRNA (miRNA) 122, which is the most common miRNA in hepatocytes. Previous studies confirmed that it functions as a tumour suppressor gene in HCC [45]. Interestingly, miRNA 122 was found to be downregulated after a SVR was achieved through DAA therapy, which may contribute to an increased risk of HCC recurrence [46]. Finally, another important study by Villani et al. demonstrated that during treatment with DAAs, the level of vascular endothelial growth factor becomes elevated significantly and remains elevated for 3 months after the cessation of DAA treatment, which may eventually lead to the development/recurrence of HCC [47]. Many studies have investigated potential predictors of HCC recurrence after DAA exposure. Table 1 summarises the studies that found independent risk factors for de novo HCC development or recurrence after DAA exposure.

**Fig. 1.** HCC occurrence rate after DAA observed by various studies. See above-mentioned references for further information.

**Fig. 2.** HCC recurrence rate after DAA observed by various studies. See above-mentioned references for further information.

Conclusions and future perspectives

While it appears that there is no increased risk of de novo HCC in cirrhotic patients receiving DAAs, the existence of early protective effects has been questioned; this suggests that continued HCC surveillance in patients with cirrhosis should be mandatory, even after achieving a SVR. Notably, most American studies and some European studies showed no increase in the risk of HCC recurrence after treatment with DAAs. However, other European, Japanese and Egyptian studies showed the opposite effect, with an increased HCC recurrence rate following DAA therapy in HCC patients; these conflicting findings indicate that geographical variations and differences in viral genotypes may play a role in HCC recurrence after DAA therapy. Some reports acknowledged that they were unable to account for geographical variations. It seems that after DAA exposure, some patients with HCV are at increased risk of de novo HCC development, and other patients with a history of treated HCC are
at increased risk of HCC recurrence. Identifying those at increased risk is very important for the management of HCC, as HCC has potentially major ramifications for the patients’ quality of life and, consequently, imposes a major burden on healthcare costs, especially in developing countries.

Conflict of interest

The authors have declared no conflict of interest

Compliance with Ethics Requirements

This article does not contain any studies with human or animal subjects.

References

[1] Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotype. Hepatology 2015;61(1):77–87.
[2] Kandeel A, Genedy M, Al-Refai S, Funnik AL, Fontanet A, Talalat M. The prevalence of hepatitis C infection in Egypt 2015: implication for future policy on prevention and treatment. Liver Int. 2017;37(1):45–53.
[3] Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin. Gastroenterol. Hepatol. 2007;5:938–45.
[4] Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of HCV-related cirrhosis in patients with sustained virological response by pegylated interferon and ribavirin. Dig. Dis. Sci. 2015;60:573–81.
[5] El Kassas M, Funk AL, Salaheldin M, Shimakawa Y, Eltabbakh M, Jean K, et al. Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: a comparative study and meta-analysis. PLoS ONE 2013;8(9):e71361.
[6] Moon C, Jung KS, Kim DY, Baackhuroo O, Park JY, Kim BK, et al. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin. Dig. Dis. Sci. 2015;60:573–81.
[7] El Kassas M, Funk AL, Salaheldin M, Shimakawa Y, Eltabbakh M, Jean K, et al. Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: a comparative study and meta-analysis. J. Viral. Hepat. 2015;22(3):203–30.
[8] Llovet JM, Villanueva A, Liver cancer: Effect of HCV clearance with direct-acting antiviral agents on HCC. Nat. Rev. Gastroenterol. Hepatol. 2016;13:561–72.
[9] Reig M, Manaflo Z, Perelló C, Ricart A, Vázquez M, Alegre S, et al. Increased rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J. Hepatol. 2016;65:719–26.
[10] Cammà C, Cabibbo G, Craxì A. Direct antiviral agents and risk for HCC early recurrence: much ado about nothing. J. Hepatol. 2016;65:861–2.
[11] Cardoso H, Vale AM, Rodrigues S, Gonçalves R, Albuquerque A, Pereira S, et al. Newly diagnosed hepatocellular carcinoma in patients with advanced HCC treated with DAAs: A prospective population study. J. Hepatol. 2018;69(2):345–52.
[12] Hasson H, Merli M, Messina E, Bhoori S, Salpietro S, Morisca G, et al. Incidence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals. J. Hepatol. 2017;67:415–7.
[13] Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, et al. Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology 2018;155(2):411–21.e4.
[14] Reig M, Angeli P, Provesan S, Noventa F, Anastassopoulou C, Cenzullo L, et al. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. J. Hepatol. 2018;69(2):345–52.
[15] Ogawa E, Furusyo N, Nomura H, Dohmen K, Higashi N, Takahashi K, Kawano A, et al. Imaging features of microvascular invasion in hepatocellular carcinoma after direct-acting antiviral therapy in HCV-related cirrhosis. EurRadiol. 2018;28:506–13.
[16] Azuma K, Satoh T, Nakamuta M, Koyanagi T, Kato M, Shimoda S, Kajiwara E, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients treated with direct-acting antivirals. J. Hepatol. 2017;66;1138–48.
Chu PS, Nakamoto N, Taniki N, Ojiro K, Amiya T, Makita Y, et al. On-treatment HCV clearance in a VA cohort. Monto A, Ryan J, Niemi E, segal M, Lanier L. J. Hepatol. 2017;66:51, 1412.

Nakao K, Miyaaki H, Ichikawa T. Antitumor function of microRNA-122 against hepatocellular carcinoma. J Gastroenterol 2014;49:589–93.

Waring JF, Dumas EO, Abel S, Coakley E, Cohen DE, Davis JW, et al. Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects. J Viral Hepat 2016;23:96–104.

Villani R, Facciorusso A, Bellanti F, Tamborra R, Piscaci A, Landriscina M, et al. DAA rapidly reduce inflammation but increase serum VEGF level: a rationale for tumor risk during anti-HCV treatment. PLoS ONE 2016;11: e0167934.

Metkic F, Schlevogt B, Deterting K, Wranke A, Smith A, Port K, et al. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. Aliment Pharmacol Ther 2018;47:516–25.

Ikeda K, Kawamura Y, Kobayashi M, Kominnami Y, Fujiiyama S, Sezaki H, et al. Direct-acting antivirals decreased tumor recurrence after initial treatment of hepatitis C virus-related hepatocellular carcinoma. Dig Dis Sci 2017;62:2932–42.

Mashita T, Jokor K, Kosakasi M, Ochi H, Osaki Y, Kojima Y, et al. Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Liver Hospital Study Group. PLoS ONE 2018;13:e0194704.

Bourliere M, Gane EJ, Jacobson I, Gordon SC, Sulkowski MS, McNabb BL, et al. Long-term follow up of patients with chronic HCV and no or minimal fibrosis shows low risk for liver-related morbidity and mortality after achieving SVR with DAA based therapy: results from the Gilead S Raji. Hepatology 2017;65:31A–9.

Issachar A, Sneh-Arbi A, Braun M, Shlomai A, Oxtrud E, Harif Y, et al. LBP-509-Occurrence and recurrence of malignancies post DAA Treatment in 5.1% of patients-single center experience. J. Hepatol. 2017;66:S97.

Zanetto A, Shalaby S, Vitale A, Mescoli C, Ferrarese A, Gambato M, et al. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals. Liver Transpl. 2017;23:1103–12.

Degasperi E, D’Ambrosio R, Sanguinoni A, Aghemo A, Soffredini R, De Nicola S, et al. Low rates of de novo or recurrent hepatocellular carcinoma in HCV cirrhotic patients treated with direct-acting antivirals (DAAs): a single-center experience. Hepatology 2017;66:46A.

Deterting K, Mauss S, Pathil A, Buggisch P, Schott E, Cornelberg M, et al. PS-096-Long-term follow-up after IFN-free therapy of advanced HCV-associated liver cirrhosis: continued improvement of liver function parameters – results from the German Hepatitis C Registry (DHHC-8). J. Hepatol. 2017;66:S55.

Ogata F, Kobayashi M, Akuta N, Osawa M, Fujiiyama S, Kawamura Y, et al. Outcome of all-oral direct-acting antiviral regimens on the rate of development of hepatocellular carcinoma in patients with Hepatitis C virus genotype 1-related chronic liver disease. Oncology 2017;93:92–8.

Nagaoi Y, Inamura M, Aikata H, Dajo K, Teraoka Y, Honda F, et al. The risks of hepatocellular carcinoma development after HCV eradication are similar in patients with genotype 1-related chronic liver disease. Oncology 2017;93:92–8.

Kwon AJ, Kim W, Fleming JA. Continued increase in de novo hepatocellular carcinoma among liver transplant registrants with hepatitis C virus infection. Hepatology 2017;66:71A.